# Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2021

- Company: [Purple Biotech LTD.](/companies/ppbt.md) (CIK 1614744)
- Form: 20-F
- Filed: 2022-03-09
- Accepted by EDGAR: Mar 9, 2022, 06:20 ET
- Period: 2021-12-31
- Accession: 0001213900-22-011191
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1614744/000121390022011191/f20f2021_purplebiotech.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1614744/000121390022011191/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Selling, general and administrative | 12 months, 2021-01-01 to 2021-12-31 | $6.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | $17.8m | us-gaap:ProfitLoss |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$374.0k | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $115.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-12-31 | $10.9m | ifrs-full:CashAndCashEquivalents |
| Total assets | at 2021-12-31 | $70.2m | ifrs-full:Assets |
| Current liabilities | at 2021-12-31 | $4.3m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2021-12-31 | $64.8m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2021-12-31 | 178,001,092 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1614744/000121390022011191/f20f2021_purplebiotech.htm

Filed Mar 9, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-011191. Last ingested by Listed: Nov 6, 2026, 18:16 ET. No prices; not investment advice.